- Home
- DVS vs VYGR Comparison
DVS vs VYGR Comparison
Compare DVS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- VYGR
- Stock Information
- Founded
- DVS 2011
- VYGR 2013
- Country
- DVS Canada
- VYGR United States
- Employees
- DVS N/A
- VYGR N/A
- Industry
- DVS
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- DVS
- VYGR Health Care
- Exchange
- DVS Nasdaq
- VYGR Nasdaq
- Market Cap
- DVS 210.3M
- VYGR 172.6M
- IPO Year
- DVS N/A
- VYGR 2015
- Fundamental
- Price
- DVS $3.33
- VYGR $2.96
- Analyst Decision
- DVS
- VYGR Strong Buy
- Analyst Count
- DVS 0
- VYGR 8
- Target Price
- DVS N/A
- VYGR $14.33
- AVG Volume (30 Days)
- DVS 369.0K
- VYGR 666.3K
- Earning Date
- DVS 08-23-2025
- VYGR 08-12-2025
- Dividend Yield
- DVS N/A
- VYGR N/A
- EPS Growth
- DVS N/A
- VYGR N/A
- EPS
- DVS N/A
- VYGR N/A
- Revenue
- DVS N/A
- VYGR $66,958,000.00
- Revenue This Year
- DVS N/A
- VYGR N/A
- Revenue Next Year
- DVS N/A
- VYGR $78.89
- P/E Ratio
- DVS N/A
- VYGR N/A
- Revenue Growth
- DVS N/A
- VYGR N/A
- 52 Week Low
- DVS $2.48
- VYGR $2.65
- 52 Week High
- DVS $4.15
- VYGR $9.21
- Technical
- Relative Strength Index (RSI)
- DVS N/A
- VYGR 41.73
- Support Level
- DVS N/A
- VYGR $3.15
- Resistance Level
- DVS N/A
- VYGR $3.79
- Average True Range (ATR)
- DVS 0.00
- VYGR 0.21
- MACD
- DVS 0.00
- VYGR -0.02
- Stochastic Oscillator
- DVS 0.00
- VYGR 1.19
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.